|
|
801 Albany Street, Suite 112
Boston, MA 02118 USA
phone:617-638-6394
fax:617-638-5661
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.adipogenix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Small molecule pharmaceuticals for obesity and its co-morbidities. |
|
| Management |
| Ed Cannon, Ph.D., President and CEO; Nils Bergenhem, Ph.D., Chief Scientific Officer; Gerri Waloga, Ph.D., Founder of AdipoGenix and vice president |
| |
|
|
| |
|
| Keywords |
| small molecule, obesity, fat cell, enzyme, metabolite, assay, screening |
|
|
|
| Description |
|
AdipoGenix, Inc. is developing small molecule pharmaceuticals to treat obesity and its co-morbidities. |
|
| Technology / Differentiation |
| AdipoGenix has developed a unique technology for identifying compounds that have a beneficial effect, reduced fat content, on this tissue consisting of: AdipoBASE, A proprietary collection of human fat cell precursors; AdipoSCREEN, A cell-based high-throughput screening technology; AdipoPATH, A panel of assays that distinguish four fat cell effects; AdipoTARGET, A portfolio of assays and pharmacological tools for key enzymes and metabolites. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members